RACC’s Oak Hill Bio Merger Brings $175M in Funding to Advance Angelman Syndrome Therapy
Market Chameleon (Mon, 27-Jul 7:15 AM ET)
RACC and Oak Hill Bio Join Forces to Push Angelman Syndrome Therapy Toward Phase 3 Milestone
Market Chameleon (Mon, 27-Jul 4:57 AM ET)
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Research Alliance III - Class A trades on the NASDAQ stock market under the symbol RACC.
As of September 3, 2026, RACC stock price declined to $12.56 with 523,994 million shares trading.
RACC has a beta of 3.05, meaning it tends to be more sensitive to market movements. RACC has a correlation of 0.07 to the broad based SPY ETF.
RACC has a market cap of $114.28 million. This is considered a Micro Cap stock.
RACC support price is $17.56 and resistance is $21.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RACC shares will trade within this expected range on the day.
